Objective. The present study aimed to investigate if a new placebo device for interferential current (IFC) that delivers current during only the first 40 seconds of stimulation is effective at promoting adequate subject blinding.
Introduction
Interferential current (IFC) therapy is a mediumfrequency current with modulated amplitude at low frequency (0-250 Hz), produced by the difference between two sinusoidal alternated medium frequency currents [1, 2] . The interference generated between these two currents maximizes its ability to penetrate the skin (lower skin impedance) and stimulate the underlying nerves and, simultaneously, reduces the undesirable stimulation of cutaneous nerves [3] . The use of IFC has been commonly reported for the promotion of symptomatic pain relief [4, 5] . Studies have shown that this current is effective in reducing pain in individuals with arthritis [5] , gonartrosis [6, 7] , psoriasis [8] , fibromyalgia [9] , primary dysmenorrhea [10] , low back pain [11] [12] [13] , and postoperative pain [14, 15] .
However, in order to examine the efficacy of any pain treatment, including IFC, it should be compared to a sham treatment methodologically adequate to allow the assessment of its physiological effect [16, 17] . Placebo effect is one that follows the administration of a treatment with an inert material (placebo), whether it is pharmacologic or not [18] .
Studies have demonstrated an association between the placebo method and endogenous opioid mechanisms that lead to a reduction in pain [19] [20] [21] . These mechanisms can be caused by response expectation; when the individual has an expectation of pain reduction after any treatment, this fact can, alone, promote the alleviation of pain [22] . Thus, any proposed analgesic treatment would be effective when its biological efficacy was proven to be superior to the effect generated by placebo therapy [16] .
Despite the growing interest in studying its effect, placebo remains a relatively unexplored area of study in the physical therapy field [23] . Two previous studies have investigated the placebo effect of interferential current [23, 24] compared to no intervention (control group). Both studies utilized a placebo method that does not release any electrical current, only displays an active indicator light to evoke the idea of an active treatment and try to convince the subjects involved in the effectiveness of therapy.
However, the lack of current sensation may induce the subjects to think that they are not receiving active treatment, not blinding the effect of therapy. Furthermore, this method has the limitation of not blinding the investigator who is applying the treatment, creating the need for a second investigator to measure the variables in order to avoid generating bias in the study [17] .
Rakel et al. [17] compared a new placebo method of transcutaneous electrical nerve stimulation (TENS) that delivers current only for the first 45 seconds of stimulation with active TENS and a device that does not deliver current (inactive placebo). This new method of investigation was able to completely blind the study investigators to the type of stimulation administered, active or placebo, unlike the inactive placebo method. Additionally, the new device did not decrease the pain of the subjects involved in the study. Therefore, this study proposes a new method of investigation through a placebo device that, once attached to the IFC device, modifies the current release, allowing it to be delivered only in the first 40 seconds of stimulation, with subsequent annulment of current. Thus, we believe that the blinding of the investigator and subject sample would be increased.
The aims of our study were to observe whether the new IFC placebo investigation method promotes adequate blinding and analyze whether its use influences the pressure pain and cutaneous thresholds, and pain intensity in relation to active IFC in healthy subjects.
Methods

Subjects
After approval by the Ethics Committee for Human Research of the Federal University of Sergipe (UFS), 75 healthy subjects, university students, mean age 20.59 (6 0.46) years, were recruited on the campus of São Crist ovão and Aracaju of the Federal University of Sergipe through personal contact in the campus facilities. Demographic information, including age, sex, height, and weight, were collected (Table 1) .
Exclusion criteria included: 1) peripheral nerve injury in the upper limbs, 2) presence of pain in the upper limbs, 3) pregnancy, 4) chronic diseases, 5) use of cardiac pacemaker, 6) epilepsy, 7) allergy to the material of the electrodes, 8) current use of analgesic medication or in the last seven days, 9) altered skin conditions or loss of sensation in the established areas of electrode placement [17] .
After providing written informed consent, the subjects were allocated into the groups by investigator 1. Randomization occurred through selection of opaque sealed envelopes containing the letters A, B, and C, identifying the sample groups. Additionally, participants were stratified by gender to ensure proportional allocation between men and women in the different study groups (Figure 1 ) [17, 25] . The sample size was calculated on the average of 25 subjects per group, at a level of significance of 0.05 and b ¼ 80%.
Study Groups
The subjects were randomly divided into three groups, described as follows: 1) active IFC (sensorial intensity): electrodes were applied to the subject's forearm and connected to an IFC device; once the IFC stimulation was applied, intensity was increased until a motor Figure 1 Study flowchart.
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contraction was produced, then the pulse amplitude was decreased to 10% below motor contraction [17] ; 2) inactive placebo: electrodes were applied in the same way and the subjects were connected to an IFC device that was turned on to appear that the device was functioning, but no stimulation was delivered; 3) new placebo: an external device, manufactured exclusively for this study, was connected to the IFC device in order to modify the release of electrical current, enabling the current to be released only during the first 40 seconds of stimulation, then cease the passage of current (adapted from the Placebo TENS [17] ).
Placebo Device Description
The placebo device was developed by Professor Elyson Adan Nunes Carvalho (PhD), Associate Professor of the Department of Electrical Engineering, Federal University of Sergipe. This device has the function to deliver interferential current to the subject for a short period of time, without letting the subject perceive the current interruption. To this end, the device has an internal resistance with a value near the resistance of human skin, and operates by selecting, through a key, if the IFC is applied to the patient or to the internal resistance of the device. This selection is performed intermittently, with a duty cycle of 0.2 ms. Thus, for a percentage of that time, the system selects the individual and for the rest of the time, the internal resistance is selected, repeating this process indefinitely.
The short time interval is enough for the subject not to feel the effects of switching, as it has the sensation of a continuous application of lesser value. At the start of application, the system delivers the current to the subject, then after 40 seconds, the current is diverted to its internal resistance.
The way it was designed, the placebo apparatus can easily be applied to other types of electrostimulation currents. It is safe for the subject and does not allow the device to recognize that the electrical current is not being delivered to the subject, avoiding false accusations of noncontact electrodes.
Subject's Assessment
Investigator 2, blinded for the group allocation, was responsible for evaluating the subjects before and after intervention. For the assessment of cutaneous sensibility and pressure pain threshold, two points in the dominant forearm of the subject were used: 1) 3 cm distally to the distal extremity of the anatomical snuff box in the midline of the muscle belly of the first dorsal interosseous palmar; and 2) on the anterior aspect of the forearm, 7.5 cm proximal to the distal wrist crease. These sites were chosen to examine the effects of IFC within the area of stimulation (hand and forearm).
Skin sensitivity was assessed by using an esthesiometry set with the Weinstein Semmer monofilaments (SorriV R , São Paulo, SP, Brazil), which consists of six monofilaments with increasing tension forces. Prior to the measurement, calibration was performed to assign pressure forces (in mN) to each of the filaments in a precision analytical balance. For the measurement of cutaneous sensory threshold, the monofilament was positioned perpendicular to the skin tissue of the individual and gently pressed until the initial curvature of the filament, then removed [26, 27] .
The monofilaments were applied in duplicate at an increasing rate of pressure exerted. The pressure force produced by the filament was considered a cutaneous sensory threshold when the subject replied that a touch sensation was felt. The subject's eyes were blindfolded during this procedure.
Pressure pain threshold (PPT) was measured through a digital pressure algometer (ImpacV R , São Paulo, SP, Brazil, probe with an area of 1 cm 2 ), which was previously calibrated. Subjects were instructed to say "stop" when the pressure sensation became painful, and this value was recorded. Three measures (in Newton) were performed at each site of measurement, and an average of them was used to record the data [17, 28, 29] . After measuring PPT, the subject was asked about the perceived pain intensity through a 11-point numerical rating scale (11-NRS).
Questions Related to IFC
By the end of the intervention, the subjects were asked about the treatment they received and their expectations: "Do you think that you received an active or placebo treatment?" Similarly, investigator 3, responsible for IFC application, was asked about his expectation regarding the group allocation of the subjects [17] .
Protocol
The participants were asked to remain seated in a comfortable upright position, with the upper limb resting on a table, during all procedures. The interventions were performed in the subject's dominant upper limb, as previously described.
Before starting the study, the IFC units were calibrated by using an oscilloscope. The limb was cleaned with 70% alcohol before marking and placement of the electrodes in it. Investigator 2 evaluated CST, PPT, and pain intensity, retiring from the room where the intervention occurred after the procedures.
Before IFC administration, all subjects were informed about the different types of intervention tested and that they would feel, or not, a sensation of numbness in the skin just below the electrodes.
Two auto-adhesive electrodes with area of 5 cm 2 (ValuTrodeV R , Fallbrook, USA), were placed on the lateral aspect of the forearm at the distal crease of the wrist Validation of a New Placebo Interferential Current Method and 10 cm proximal to the same [29] and IFC was administered for 40 minutes by investigator 3. A beat frequency (amplitude-modulated frequency; AMF) of 100 Hz was used in this study. In order to achieve this AMF current, two separate medium frequency currents, one at 4000 Hz and the other at 4100 Hz, were crossed within the stimulator. The placebo device was connected to all IFC devices, but was only activated in the new placebo group, blinding both subjects and investigator (Figure 2) .
By the end of the intervention, investigator 2 returned to the room to reassess the parameters and, right after, both investigator 3 and the subject were questioned by investigator 1 about which group each individual was allocated into, with the following response options: placebo or active IFC.
Statistical Analysis
Data were initially transported to a spreadsheet in Excel for Windows 2007 and then to SPSS, version 16.0. Data from each group was recorded as a percentage of change (between pre-and post-treatment). Scores from the initial assessment were considered baseline values. Then, we made a subtraction between pre-and posttreatment measures and used this final value as an absolute difference. After performing a Shapiro-Wilk normality test, and considering that the data followed a parametric analysis, a one-way ANOVA test was used to analyze independent measures, followed by the Bonferroni test. A p value < 0.05 was considered statistically significant. Results
Placebo's Suitability
The new placebo method was able to completely mask research investigator 3 (100%), inducing the belief that an active treatment was being applied throughout the intervention period. In contrast, the inactive placebo method did not mask the intervention (0%), whereas investigator 3 who had applied answered correctly that a placebo treatment was used in all subjects allocated to this group. Furthermore, investigator 3 answered correctly that all subjects allocated to the active IFC group received an active treatment.
Fifteen of the 25 subjects assigned to the new placebo group answered that they had received an active treatment. Thus, this new method was able to mask 60% of the individuals belonging to this group. Regarding the inactive placebo, it managed to mask only 9 of the 26 subjects who received this intervention, corresponding to 34% of the sample. Treatment with active IFC was correctly identified by 20 of the 24 subjects in the group (approximately 83%; p < 0.02).
Treatment Effects
There were no significant changes in the PPT, CST, or pain intensity after intervention among the three groups of study. However, those individuals allocated to the active IFC group, which received stimulation intensities greater than 17 mA (value determined by analysis of median stimulation intensities in the active IFC group, corresponding to 14 of 24 subjects allocated to this group) obtained a significant change in all the parameters analyzed (p < 0.0001). Ten subjects who received stimulation intensity below or equal to 17 mA had no significant increase in CST and PPT or significant reduction in pain intensity (p > 0.05).
The new placebo group had no significant changes in PPT, but this group had a higher percentage of change (4%) when compared to the inactive placebo (1%). The active IFC group, at high intensity, showed a significant increase in PPT, around 30% after the intervention (p < 0.0001) (Figure 3) . Similarly, the new placebo device caused greater changes in CST (15%) than inactive placebo (2%), although those changes were not significant. Significance was found in the treatment with high-intensity active IFC, Figure 2 IFC unit attached to the placebo device. Figure 3 Percentage of change in pressure pain threshold. Data presented as mean 6 standard error of the mean. *p < 0.0001 compared to placebo group and active IFC group stimulated at low current intensity. ANOVA for independent measures followed by Bonferroni test.
in which the increase in CST was of 45%, while the lowintensity active treatment increased by only 18% in CST and did not represent a significant change (Figure 4 ).
Regarding the pain intensity, there was a significant reduction of 55% in subjects stimulated with high-intensity IFC when compared to the new placebo (12%) and the inactive placebo (5%). IFC at low intensities had no statistically significant differences (20%; Figure 5 ).
Discussion
Placebo's Suitability
In the current study, the new placebo method completely masked the research investigator, whereas the old placebo, which did not lead to muscle contraction, allowed the researcher to easily identify that it was an inactive treatment. Our findings corroborate those found by Rakel et al. [17] on the validation of the placebo TENS method. The application of the new placebo method, being similar to the application of active IFC, which causes a motor contraction initially, induced the investigator to think that an active treatment was being performed. Therefore, the researcher failed to distinguish which treatment, active or placebo, was applied.
Given the above, this new method allows that a single researcher can apply the treatment and assess the results, thereby reducing search costs and any bias that may be generated by the investigator [17] . The investigators who know the treatment applied and its possible effects may inadvertently influence their respondents to produce results consistent with their expectations [16, 17, 30] . This approach can lead the subject to overestimate the treatment, resulting in an expectation bias [17] .
Another way to mask the effect of a treatment is when it is not compared to a placebo able to fool the research subject. The placebo effect is caused not by the physical properties of the substance or procedure used but by the meaning assigned to it [20] .
One mechanism of the placebo effect is represented by the response expectation [22] . The expectation constitutes the probability of a procedure or agent to promote the alleviation of pain [31] . Thus, if the individual has an expectation of pain reduction after administration of a placebo treatment, this fact alone can generate the subsequent relief of pain [22, 32, 33] .
Scientific evidence has demonstrated an association of the endogenous opioid system in the mediation of placebo effect under conditions of analgesia expectation [19] [20] [21] . Thus, for a treatment to be considered effective, its effect must be greater than the analgesia induced by the placebo effect produced in the body [16] . Therefore, the use of a placebo able to blind the subject would avoid the overestimation of the treatment effect [33] .
In the present study, 60% of individuals allocated to the new placebo group believed that they received an active treatment versus 34% for the inactive placebo. Our hypothesis is that the paresthesic sensation that occurs in the first 40 seconds of the new placebo stimulation produces higher expectations in individuals than the old placebo method, in which no current is released. The early sensation of current flow induces the subjects to think they are receiving an active treatment.
In addition, electrical stimulation may be perceived by subjects as a threat [23] . Thus, anxiety associated with an electrical experimental procedure could lead to an increased need for pain relief and, therefore, a greater response to placebo can be activated [23, 24] . Therefore, this new method would produce a true placebo effect Figure 4 Percentage of change in cutaneous sensory threshold. Data presented as mean 6 standard error of the mean. *p < 0.0001 compared to placebo group and active IFC group stimulated at low current intensity. ANOVA for independent measures followed by Bonferroni test. Figure 5 Percentage of change in pain intensity. Data presented as mean 6 standard error of the mean. *p < 0.0001 compared to placebo group and active IFC group stimulated at low current intensity. ANOVA for independent measures followed by Bonferroni test.
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and, consequently, would promote a greater analgesic effect than the inactive placebo method, as demonstrated by our results.
Despite this, many studies use the inactive placebo to test the effectiveness of IFC [7, 14, 23, 34, 35] . Fuentes et al. [23] demonstrated the efficacy of active IFC compared to a placebo condition (inactive placebo) and control, in which no treatment is applied and the research subject knows that there is no intervention. In this study, the placebo and control methods used were not effective in reducing pain, and the effects did not differ among them. Since in the control group, no means of masking therapy were used, these results may signify the importance of the paresthesia feeling in inducing expectation of pain relief, and consequently a greater placebo response.
In relation to the degree of blinding of active treatment, an important finding of our study is the high percentage of correct answers from subject and researcher, similar to the data found by Rakel et al. [17] . These data confirm the need for an appropriate placebo, since there is a facility of identification in the active treatment, leading to a possible overestimation of the therapeutic effect.
Treatment Effects
In accordance with the findings of Rakel et al. [17] , none of the studied forms of placebo resulted in a significant change in pressure pain threshold, cutaneous sensory threshold, or pain intensity; neither of the two placebo methods were able to significantly alter these parameters.
Additionally, the active IFC also produced no significant changes in the PPT, CST, or pain intensity. However, significant changes in these parameters were observed in this group when compared to both placebo groups. Subjects who received high stimulation intensities in the active IFC group showed higher PPT and CST and lower pain intensity than those stimulated at low intensities when compared to both placebo groups.
Previous studies that used TENS as a therapeutic resource demonstrated that the intensity adjustment has an important role in its hypoalgesic effect [17, 28, 29, 36, 37] . In these studies, subjects that were stimulated with high intensity TENS experienced a greater analgesic effect than those stimulated at low current intensities, similar to our findings with IFC.
Study Limitations
No specific questionnaires were used to quantify the expectation generated by the new placebo method in the study subjects. Only a question about the masking of the therapy was used to estimate this expectation. In addition, more research should be carried out to prove the efficacy of the new placebo on subject and investigator blinding.
The mechanisms involved in expectations are dynamic and their effects may differ depending on the type of pain involved (clinical or experimental) [23, 38] . Our sample consisted of healthy individuals with mechanically induced pain; however, research with subjects with acute or chronic painful conditions should be performed to demonstrate the effects of both placebo methods in clinical situations. An important finding was the possible correlation between the intensity of stimulation and the hypoalgesic effect caused by IFC. Future studies that identify the influence of stimulation intensity in IFC hypoalgesia are fundamental to understanding the analgesic efficacy of this current.
Conclusions
The new placebo method of interferential current was efficient in completely blinding the investigator to the type of intervention. Thus, it provides advantages in cost and research protocol, allowing the same investigator to apply the treatment and evaluate the results. Additionally, this new device was able to mask the research subjects more efficiently than the old placebo, promoting a true placebo method. This method was able to determine the true efficacy of IFC, and demonstrated the importance of its use in future clinical studies.
